Compendium of Cancer Genome Aberrations

Volunteer Assignments and Opportunities: Difference between revisions

← Older editNewer edit →
VisualWikitext
No edit summary
Snehal.Patel (talk | contribs)
editor
270 edits
No edit summary
(88 intermediate revisions by 6 users not shown)
Line 14: Line 14:
|
|
|
|
|PENDING
|complete
|
|
|Fabiola Quintero-Rivera (FQR)
|Fabiola Quintero-Rivera (FQR)
Line 24: Line 24:
|
|
|
|
|Complete
|complete
|
|
|FQR
|FQR
Line 34: Line 34:
|
|
|
|
|PENDING
|complete
|
|
|FQR
|FQR
Line 44: Line 44:
|
|
|
|
|PENDING
|complete
|
|
|FQR
|FQR
Line 54: Line 54:
|
|
|
|
|PENDING
|complete
|
|
|FQR
|FQR
|
|8/4/2020 before submission
|
|
|-
|-
|    Essential  Thrombocythaemia (ET)||Disease
|    Essential  Thrombocythaemia (ET)||Disease
|Rebecca Smith (trainee) + faculty TBD
|Rebecca Smith (trainee) + Fabiola Quintero-Rivera
|
|
|
|
|PENDING
|complete/pending faculty review
|
|
|FQR
|FQR
Line 71: Line 71:
|-
|-
|    Chronic Eosinophilic  Leukemia, Not Otherwise Specified||Disease
|    Chronic Eosinophilic  Leukemia, Not Otherwise Specified||Disease
|Mark Evans (trainee), Fabiola Quintero-Rivera
|(trainee), Daynna J.Wolff
|
|
|
|
|PENDING
|pending faculty review
|
|
|FQR
|FQR
Line 81: Line 81:
|-
|-
|    Myeloproliferative  Neoplasm (MPN), Unclassifiable||Disease
|    Myeloproliferative  Neoplasm (MPN), Unclassifiable||Disease
|Mark Evans (trainee)+ Fabiola Quintero-Rivera
|Thomas Lee
|
|8/17/2020
|
|9/7/2020
|PENDING
|complete
|
|
|FQR
|FQR
Line 90: Line 90:
|
|
|-
|-
|'''''Mastocytosis'''''||'''''Overview'''''||
|'''''Mastocytosis'''''||'''''Overview'''''||'''Shashi Shetty, Ph.D.'''
|
|
|
|
|
|complete
| ||FQR
| ||FQR
|
|
Line 99: Line 99:
|-
|-
|    Cutaneous  Mastocytosis||Disease
|    Cutaneous  Mastocytosis||Disease
|Thuy Phung
|Thuy Phung/Shuo-Shawn Liu
|
|
|
|
|PENDING
|complete/pending adding content online as of 2/4/21
|
|
|FQR
|FQR
Line 112: Line 112:
|
|
|
|
|PENDING
|complete
|
|
|FQR
|FQR
Line 119: Line 119:
|-
|-
|    Mast Cell Sarcoma||Disease
|    Mast Cell Sarcoma||Disease
|Thuy Phung
|Thuy Phung +Jordan Lowery
|
|
|
|
|PENDING
|complete
|
|
|FQR
|FQR
Line 131: Line 131:
|
|
|
|
|PENDING
|complete
|
|
|FQR
|FQR
Line 224: Line 224:
|    Juvenile  Myelomonocytic Leukemia (JMML)||Disease||Sarah Rapisardo
|    Juvenile  Myelomonocytic Leukemia (JMML)||Disease||Sarah Rapisardo
|
|
|
|9/1/20
|PENDING
|PENDING
|
|
Line 234: Line 234:
|
|
|
|
|PENDING
|complete
|
|
|FQR
|FQR
Line 243: Line 243:
|
|
|
|
|PENDING
|complete
|
|
|FQR
|FQR
Line 251: Line 251:
|'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''||Teresa Smolarek?
|'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''||Teresa Smolarek?
|
|
|
|9/1/20
|
|pending
|
|
|FQR
|FQR
Line 260: Line 260:
|    Myelodysplastic  Syndrome (MDS) with Single Lineage Dysplasia||Disease||Xiaoli Du(trainee) +Teresa Smolarek
|    Myelodysplastic  Syndrome (MDS) with Single Lineage Dysplasia||Disease||Xiaoli Du(trainee) +Teresa Smolarek
|
|
|
|9/1/20
|PENDING
|PENDING
|
|
Line 285: Line 285:
|
|
|-
|-
|    Myelodysplastic syndrome with multilineage dysplasiaMyelodysplastic Syndrome (MDS) with  Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|    Myelodysplastic Syndrome (MDS) with  Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|
|
|
|9/1/20
|PENDING
|PENDING
|
|
Line 296: Line 296:
|    Myelodysplastic  Syndrome (MDS) with Excess Blasts||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|    Myelodysplastic  Syndrome (MDS) with Excess Blasts||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|
|
|
|9/1/20
|PENDING
|PENDING
|
|
Line 315: Line 315:
|
|
|
|
|PENDING
|complete
|
|
|FQR
|FQR
Line 323: Line 323:
|    Refractory Cytopenia  of Childhood||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|    Refractory Cytopenia  of Childhood||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|
|
|
|9/1/20
|PENDING
|PENDING
|
|
Line 344: Line 344:
|
|
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|
|04/26/2021 -MS (re-review)
|
|
|-
|-
Line 352: Line 352:
|Complete
|Complete
| ||JH / MS
| ||JH / MS
|
|03/01/2021-MS (re-review)
|
|
|-
|-
Line 360: Line 360:
|PENDING
|PENDING
| ||JH / MS
| ||JH / MS
|
|04/26/2021 -MS (re-review)
|
|
|-
|-
Line 366: Line 366:
|
|
|
|
|PENDING
|Complete
| ||JH / MS
| ||JH / MS
|
|03/01/2021-MS
|
|
|-
|-
Line 374: Line 374:
|
|
|
|
|PENDING
|Complete
| ||JH / MS
|02/03/2021||JH / MS
|
|
|
|
Line 382: Line 382:
|
|
|
|
|PENDING
|Complete
| ||JH / MS
| ||JH / MS
|
|03/02/2021-MS
|
|
|-
|-
Line 392: Line 392:
|Complete
|Complete
| ||JH / MS
| ||JH / MS
|
|03/02/2021-MS (re-review)
|
|
|-
|-
Line 400: Line 400:
|Complete
|Complete
| ||JH / MS
| ||JH / MS
|
|04/26/2021 -MS (re-review)
|
|
|-
|-
Line 409: Line 409:
|
|
|JH / MS
|JH / MS
|
|03/01/2021-MS (re-review)
|
|
|-
|-
Line 417: Line 417:
|Complete
|Complete
| ||JH / MS
| ||JH / MS
|
|04/26/2021-MS (re-review)
|
|
|-
|-
Line 425: Line 425:
|Complete
|Complete
| ||JH / MS
| ||JH / MS
|
|03/01/2021-MS (re-review)
|
|
|-
|-
Line 433: Line 433:
|Complete
|Complete
| ||JH / MS
| ||JH / MS
|
|03/01/2021-MS (re-review)
|
|
|-
|-
Line 441: Line 441:
|Complete
|Complete
| ||JH / MS
| ||JH / MS
|
|03/01/2021-MS (re-review)
|
|
|-
|-
Line 449: Line 449:
|Complete
|Complete
| ||JH / MS
| ||JH / MS
|
|02/24/2021-MS (re-review)
|
|
|-
|-
Line 674: Line 674:
| ||JH / MS
| ||JH / MS
|
|
|Check reference format
|
|-
|-
|    Mixed Phenotype Acute Leukemia (MPAL),  T/Myeloid, Not Otherwise Specified||Disease||Fabiola Quintero-Rivera
|    Mixed Phenotype Acute Leukemia (MPAL),  T/Myeloid, Not Otherwise Specified||Disease||Fabiola Quintero-Rivera
Line 684: Line 684:
|
|
|-
|-
|    ??Mixed-Phenotype Acute Leukaemia, Not  Otherwise Specified (NOS), Rare Types||Disease||
|    Mixed-Phenotype Acute Leukemia, Not  Otherwise Specified (NOS), Rare Types||Disease||Daynna Wolff+ Elicia Goodale (resident)
|
|
|
|
|??
|PENDING
| ||JH / MS
| ||JH / MS
|
|
|
|
|-
|-
|    ??Acute Leukaemias of Ambiguous Lineage,  Not Otherwise Specified (NOS)||Disease||
|    Acute Leukemias of Ambiguous Lineage,  Not Otherwise Specified (NOS)||Disease||Daynna Wolff+Madison Hannay or Elicia Goodale (residents)
|
|
|
|
|??
|PENDING
| ||JH / MS
| ||JH / MS
|
|
Line 757: Line 757:
|
|
|-
|-
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||Afia Hasnain + Yassmine Akkari
|
|
|
|
|
|PENDING
| ||YA
| ||YA
|
|
Line 774: Line 774:
|
|
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma with  t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease||
|    B-Lymphoblastic Leukemia/Lymphoma with  t(12;21)(p13.2;q22.1); ETV6-RUNX1||Disease||Marilena Melas + Yassmine Akkari
|
|
|
|
|
|PENDING
| ||YA
| ||YA
|
|
|
|
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma with  Hyperdiploidy||Disease||
|    B-Lymphoblastic Leukemia/Lymphoma with  Hyperdiploidy||Disease||Afia Hasnain + Yassmine Akkari
|
|
|
|
|
|PENDING
| ||YA
| ||YA
|
|
Line 801: Line 801:
|
|
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma with  t(5;14)(q31.1;q32.1); IGH/IL3||Disease||
|    B-Lymphoblastic Leukemia/Lymphoma with  t(5;14)(q31.1;q32.1); IGH/IL3||Disease||Binu Porath + Linda Cooley
|
|
|
|
|
|PENDING
| ||YA
| ||YA
|
|
|
|
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma with  t(1;19)(q23;p13.3); TCF3-PBX1||Disease||
|    B-Lymphoblastic Leukemia/Lymphoma with  t(1;19)(q23;p13.3); TCF3-PBX1||Disease||Binu Porath + Linda Cooley
|
|
|
|
|
|PENDING
| ||YA
| ||YA
|
|
Line 826: Line 826:
|
|
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma with  iAMP21||Disease||
|    B-Lymphoblastic Leukemia/Lymphoma with  iAMP21||Disease||Holli Drendel
|
|
|
|
|
|PENDING
| ||YA
| ||YA
|
|
|
|
|-
|-
|    B-Lymphoblastic Leukemia/Lymphoma, Not  Otherwise Specified||Disease||
|    B-Lymphoblastic Leukemia/Lymphoma, Not  Otherwise Specified||Disease||Holli Drendel
|
|
|
|
|
|PENDING
| ||YA
| ||YA
|
|
|
|
|-
|-
|'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''||
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4
|Disease
|Diana Rush
|
|
|
|
|PENDING
|
|
| ||YA
|YA
|
|
|
|NON-WHO ENTITY
|-
|-
|Early T-Cell Precursor Lymphoblastic Leukemia||Disease||
|B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6
|Disease
|Celeste Eno
|
|
|
|
|PENDING
|
|
| ||YA
|YA
|
|
|
|NON-WHO ENTITY
|-
|-
|NK-Lymphoblastic Leukemia/Lymphoma||Disease||
|B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements
|Disease
|Marilena Melas
|
|
|
|
|PENDING
|
|
| ||YA
|YA
|
|
|
|NON-WHO ENTITY
|-
|-
|B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements
|B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions
|Disease
|Disease
|Helene Bruyere
|Chenkai Ma
|
|
|
|
Line 877: Line 886:
|NON-WHO ENTITY
|NON-WHO ENTITY
|-
|-
| || ||
|B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19)
|Disease
|Celeste Eno
|
|
|
|
|PENDING
|
|
| ||
|YA
|
|
|
|NON-WHO ENTITY
|-
|-
|'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''||
|B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
|Disease
|Alaa Koleilat
|
|
|
|
|PENDING
|
|
| ||Snehal Patel (SP)
|YA
|
|
|
|NON-WHO ENTITY
|-
|-
|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||Honey Reddi
|'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''||Fei Yang
|
|
|
|
|PENDING
|PENDING
|
| ||YA
|SP
|
|
|
|
|-
|-
|       Monoclonal B-cell  Lymphocytosis||Disease||Honey Reddi
|Early T-Cell Precursor Lymphoblastic Leukemia||Disease||Fei Yang
|
|
|
|
|PENDING
|PENDING
|
| ||YA
|SP
|
|
|
|
|-
|-
|B-cell Prolymphocytic Leukemia||Disease||Honey Reddi
|NK-Lymphoblastic Leukemia/Lymphoma||Disease||Fei Yang
|
|
|
|
|PENDING
|PENDING
| ||YA
|
|
|SP
|
|
|-
| || ||
|
|
|-
|Splenic Marginal Zone Lymphoma||Disease||Snehal Patel
|
|
|
|
|Complete
| ||
|
|
|SP
|
|
|Malini to review
|-
|-
|Hairy Cell Leukemia||Disease||Snehal Patel
|'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''||
|
|
|
|
|
|Complete
| ||Snehal Patel (SP)
|
|
|SP
|
|
|Malini to review
|-
|-
|'''''Splenic B-cell Lymphoma/Leukemia, Unclassifiable'''''||'''''Overview'''''||Snehal Patel
|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||
|
|
|
|
|
|Complete
|
|
|SP
|SP
|
|
|Malini to review
|
|-
|-
|    Splenic Diffuse Red  Pulp Small B-cell Lymphoma||Disease||Snehal Patel
|       Monoclonal B-cell Lymphocytosis||Disease||
|
|
|
|
|
|Complete
|
|
|SP
|SP
|
|
|Malini to review
|
|-
|-
|    Hairy Cell Leukemia Variant||Disease||Snehal Patel
|B-cell Prolymphocytic Leukemia||Disease||
|
|
|
|
|
|Complete
|
|
|SP
|SP
|
|
|Malini to review
|
|-
|-
|Lymphoplasmacytic Lymphoma||Disease||Honey Reddi
|Splenic Marginal Zone Lymphoma||Disease||Snehal Patel
|
|
|
|
|PENDING
|Complete
|
|
|SP
|SP
Line 974: Line 984:
|
|
|-
|-
|   Waldenstrom  Macroglobulinemia||Disease||Honey Reddi
|Hairy Cell Leukemia||Disease||Snehal Patel
|
|
|
|
|PENDING
|Complete
|
|
|SP
|SP
Line 983: Line 993:
|
|
|-
|-
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
|'''''Splenic B-cell Lymphoma/Leukemia, Unclassifiable'''''||'''''Overview'''''||Snehal Patel
|
|
|
|
|Complete
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|'''''Heavy Chain Diseases'''''||'''''Overview'''''||
|    Splenic Diffuse Red  Pulp Small B-cell Lymphoma||Disease||Snehal Patel
|
|
|
|
|Complete
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|    Mu Heavy Chain Disease||Disease||
|    Hairy Cell Leukemia Variant||Disease||Snehal Patel
|
|
|
|
|Complete
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|   Gamma Heavy Chain  Disease||Disease||
|Lymphoplasmacytic Lymphoma||Disease||
|
|
|
|
|
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|    Alpha Heavy Chain Disease||Disease||
|   Waldenstrom Macroglobulinemia||Disease||
|
|
|
|
|
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|Plasma Cell Neoplasms||'''''Overview'''''||Zhenya Tang
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
|
|
|
|
|PENDING
|
|
|SP
| ||SP
|
|
|
|
|-
|-
|   Non-IgM Monoclonal  Gammopathy of Undetermined Significance||Disease||Zhenya Tang
|'''''Heavy Chain Diseases'''''||'''''Overview'''''||
|
|
|
|
|PENDING
|
|
|SP
| ||SP
|
|
|
|
|-
|-
|    Plasma Cell Myeloma||Disease||Zhenya Tang/Huang Mo (trainee)
|    Mu Heavy Chain  Disease||Disease||
|
|
|
|
|PENDING
|
|
|SP
| ||SP
|
|
|
|
|-
|-
|    Plasma Cell Myeloma Variants||Disease||Zhenya Tang
|   Gamma Heavy Chain Disease||Disease||Manisha Sutariya
|
|
|
|
|PENDING
|Complete
|
|5/26/2021||SP
|SP
|
|
|
|
|-
|-
|    Plasmacytoma||Disease||Zhenya Tang
|    Alpha Heavy Chain  Disease||Disease||
|
|
|
|
|PENDING
|
|
|SP
| ||SP
|
|
|
|
|-
|-
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||
|Plasma Cell Neoplasms||'''''Overview'''''||Zhenya Tang
|
|
|
|
|PENDING
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|           Primary Amyloidosis||Disease||
|   Non-IgM Monoclonal Gammopathy of Undetermined Significance||Disease||Zhenya Tang
|
|
|
|
|PENDING
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|           Light Chain  and Heavy Chain Deposition Disease||Disease||
|    Plasma Cell Myeloma||Disease||Zhenya Tang/Huang Mo (trainee)
|
|
|
|
|PENDING
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||
|    Plasma Cell Myeloma Variants||Disease||Fariborz Rashid-Kolvear
|
|
|
|
|PENDING
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|         POEMS Syndrome||Disease||
|    Plasmacytoma||Disease||Zhenya Tang
|
|
|
|
|PENDING
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|         TEMPI Syndrome||Disease||
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||
|
|
|
|
Line 1,116: Line 1,131:
|
|
|-
|-
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Zhenya Tang & Trainee
|           Primary Amyloidosis||Disease||
|
|
|
|
|PENDING
|
|
|SP
| ||SP
|
|
|
|
|-
|-
|Nodal Marginal Zone Lymphoma||Disease||
|           Light Chain  and Heavy Chain Deposition Disease||Disease||
|
|
|
|
Line 1,133: Line 1,147:
|
|
|-
|-
|    Paediatric Nodal  Marginal Zone Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||
|
|
|
|
|PENDING
|
|
|SP
| ||SP
|
|
|
|
|-
|-
|Follicular Lymphoma||Disease||Ruthann Pfau
|         POEMS Syndrome||Disease||
|
|
|
|
|PENDING
|
|
|SP
| ||SP
|
|
|
|
|-
|-
|    Testicular Follicular  Lymphoma||Disease||Ruthann Pfau
|         TEMPI Syndrome||Disease||
|
|
|
|
|PENDING
|
|
|SP
| ||SP
|
|
|
|
|-
|-
|    In Situ Follicular Neoplasia||Disease||Ruthann Pfau
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Whayoung Lee, trainee)/Fabiola Quintero-Rivera
|
|3/9/21
|
|
|PENDING
|PENDING
Line 1,169: Line 1,180:
|
|
|-
|-
|    Duodenal-Type  Follicular Lymphoma||Disease||Ruthann Pfau
|Nodal Marginal Zone Lymphoma||Disease||Shivani Golem
|
|
|
|
|PENDING
|Complete
|
|5/28/2021||SP
|SP
|
|
|
|
|-
|-
|Paediatric-Type Follicular Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
|    Paediatric Nodal  Marginal Zone Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
|
|
|
|
|PENDING
|Complete
|
|11/11/2020
|SP
|SP
|
|
|
|
|-
|-
|Large B-cell Lymphoma with IRF4 Rearrangement||Disease||
|Follicular Lymphoma||Disease||Ruthann Pfau
|
|
|
|
|PENDING
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|Primary Cutaneous Follicle Centre Lymphoma||Disease||
|    Testicular Follicular  Lymphoma||Disease||Ruthann Pfau
|
|
|
|
|PENDING
|
|
| ||SP
|SP
|
|
|
|
|-
|-
|Mantle Cell Lymphoma||Disease||Mahsa Khanlari
|    In Situ Follicular  Neoplasia||Disease||Ruthann Pfau
|
|
|
|
|PENDING - due 8/15/20
|PENDING
|
|
|SP
|SP
Line 1,212: Line 1,224:
|
|
|-
|-
|    Leukemic Non-Nodal Mantle Cell Lymphoma||Disease||Mahsa Khanlari
|    Duodenal-Type Follicular Lymphoma||Disease||Ruthann Pfau
|
|
|
|
|PENDING - due 8/31/20
|PENDING
|
|
|SP
|SP
Line 1,221: Line 1,233:
|
|
|-
|-
|    In Situ Mantle Cell  Neoplasia||Disease||Mahsa Khanlari
|Paediatric-Type Follicular Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee)
|
|
|
|
|PENDING - due 8/15/20
|Complete
|
|8/16/2020
|SP
|SP
|
|
|
|
|-
|-
| || ||
|Large B-cell Lymphoma with IRF4 Rearrangement||Disease||Afia Hasnaid
|
|9/30/20
|Complete
|5/26/2021||SP
|
|
|
|-
|Primary Cutaneous Follicle Centre Lymphoma||Disease||Shivani Golem
|
|
|
|
| ||
|PENDING
| ||SP
|
|
|
|
|-
|-
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified||Disease||Ashwini Yenamandra
|Mantle Cell Lymphoma||Disease||Mahsa Khanlari
|
|
|
|8/15/20
|PENDING
|PENDING
|
|
|Greg Corboy (GC)
|SP
|
|
|
|
|-
|-
|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease||
|    Leukemic Non-Nodal  Mantle Cell Lymphoma||Disease||
|
|
|
|
|
|
| ||GC
|
|SP
|
|
|
|
|-
|-
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||
|    In Situ Mantle Cell  Neoplasia||Disease||
|
|
|
|
|
|
|
| ||GC
|SP
|
|
|
|
|-
|-
|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease||
| || ||
|
|
|
|
|
|
| ||GC
| ||
|
|
|
|
|-
|-
|EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified||Disease||Ashwini Yenamandra
|
|
|
|
|PENDING
|
|
| ||GC
|Greg Corboy (GC)
|
|
|
|
|-
|-
|EBV-Positive Mucocutaneous Ulcer||Disease||
|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease||
|
|
|
|
Line 1,287: Line 1,310:
|
|
|-
|-
|Diffuse Large B-cell Lymphoma Associated with Chronic  Inflammation||Disease||
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||
|
|
|
|
Line 1,295: Line 1,318:
|
|
|-
|-
|    Fibrin-Associated  Diffuse Large B-cell Lymphoma||Disease||
|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease||
|
|
|
|
Line 1,303: Line 1,326:
|
|
|-
|-
|Lymphomatoid Granulomatosis||Disease||
|EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise  Specified (NOS)||Disease||
|
|
|
|
Line 1,311: Line 1,334:
|
|
|-
|-
|Primary Mediastinal (Thymic) Large B-cell Lymphoma||Disease||
|EBV-Positive Mucocutaneous Ulcer||Disease||
|
|
|
|
Line 1,319: Line 1,342:
|
|
|-
|-
|Intravascular Large B-cell Lymphoma||Disease||
|Diffuse Large B-cell Lymphoma Associated with Chronic  Inflammation||Disease||
|
|
|
|
Line 1,327: Line 1,350:
|
|
|-
|-
|ALK-Positive Large B-cell Lymphoma||Disease||
|    Fibrin-Associated  Diffuse Large B-cell Lymphoma||Disease||
|
|
|
|
Line 1,335: Line 1,358:
|
|
|-
|-
|Plasmablastic Lymphoma||Disease||Mark Evans (trainee), Fabiola Quintero-Rivera
|Lymphomatoid Granulomatosis||Disease||
|
|
|
|
|
|Complete
| ||GC
|
|
|-
|Primary Mediastinal (Thymic) Large B-cell Lymphoma||Disease||
|
|
|
| ||GC
|
|
|-
|Intravascular Large B-cell Lymphoma||Disease||
|
|
|
| ||GC
|
|
|-
|ALK-Positive Large B-cell Lymphoma||Disease||
|
|
|
| ||GC
|
|
|-
|Plasmablastic Lymphoma||Disease||Mark Evans (trainee), Fabiola Quintero-Rivera
|
|
|Complete
| ||GC
| ||GC
|
|
Line 1,383: Line 1,438:
|
|
|-
|-
|Burkitt Lymphoma||Disease||
|Burkitt Lymphoma||Disease||Becky Leung (trainee), Greg Corboy
|
|3/11/21
|
|
|
|PENDING
| ||GC
| ||GC
|
|
Line 1,487: Line 1,542:
|
|
|-
|-
|  Systemic EBV-Positive  T-cell Lymphoma of Childhood||Disease||
|  Systemic EBV-Positive  T-cell Lymphoma of Childhood||Disease||Lisa Lansdon (trainee)
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
Line 1,547: Line 1,602:
|
|
|
|
|PENDING
|Complete
|
|1/21/2021
|SP
|SP
|
|
Line 1,583: Line 1,638:
|
|
|
|
|PENDING
|Complete
| ||SP
|1/21/2021
|SP
|
|
|
|
Line 1,596: Line 1,652:
|
|
|-
|-
|Mycosis Fungoides||Disease||
|Mycosis Fungoides||Disease||Daynna Wolff, Jane Scribner (trainee)
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|Sézary Syndrome||Disease||
|Sézary Syndrome||Disease||Daynna Wolff, Madison Hannay (trainee)
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
Line 1,710: Line 1,766:
|
|
|-
|-
|     Nodal Peripheral  T-cell Lymphoma with T Follicular Helper Phenotype||Disease||
|     Nodal Peripheral  T-cell Lymphoma with T Follicular Helper Phenotype||Disease||Hans Hamnvåg
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
Line 1,757: Line 1,813:
|
|
|
|
| ||Associate Editor??
| ||Greg Corboy (GC)
|
|
|
|
Line 1,765: Line 1,821:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,773: Line 1,829:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,781: Line 1,837:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,789: Line 1,845:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,797: Line 1,853:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,805: Line 1,861:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,813: Line 1,869:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,821: Line 1,877:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,829: Line 1,885:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,837: Line 1,893:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,848: Line 1,904:
|PENDING
|PENDING
|
|
|
|GC
|
|
|
|
Line 1,856: Line 1,912:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,864: Line 1,920:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,872: Line 1,928:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,880: Line 1,936:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,888: Line 1,944:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,896: Line 1,952:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,904: Line 1,960:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,912: Line 1,968:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,920: Line 1,976:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,928: Line 1,984:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,936: Line 1,992:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,944: Line 2,000:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,952: Line 2,008:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,960: Line 2,016:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,968: Line 2,024:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,976: Line 2,032:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 1,984: Line 2,040:
|
|
|
|
| ||
| ||GC
|
|
|
|
Line 2,152: Line 2,208:
!'''Gene'''
!'''Gene'''
!'''Author'''
!'''Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Associate Editor'''
!Author Content
!'''Date of Last Editor Review'''
(Pending or Complete)
!'''Notes'''
!Editor Reviewed (Date)
!Notes
|-
|-
|BCR
|BCR
|Brian Davis
|Brian Davis
|
|
|Complete (8/10/18)
|
|Complete
|8/10/18
|
|
|
|
|
Line 2,168: Line 2,229:
|Brian Davis
|Brian Davis
|
|
|Complete (4/16/19)
|
|Complete
|4/16/19
|
|
|
|
|
Line 2,175: Line 2,239:
|Brian Davis
|Brian Davis
|
|
|Complete (6/9/19)
|
|Complete
|6/9/19
|
|
|
|
|
Line 2,182: Line 2,249:
|Brian Davis
|Brian Davis
|
|
|Complete (5/23/19)
|
|Complete
|5/23/19
|
|
|
|
|
Line 2,189: Line 2,259:
|Brian Davis
|Brian Davis
|
|
|Complete (8/6/18)
|
|Complete
|8/6/18
|
|
|
|
|
Line 2,196: Line 2,269:
|Kay Weng Choy
|Kay Weng Choy
|
|
|Complete (
|
|Complete
|
|
|
|
|
|
Line 2,203: Line 2,279:
|Kay Weng Choy
|Kay Weng Choy
|
|
|Complete (
|
|Complete
|
|
|
|
|
|
Line 2,210: Line 2,289:
|Kay Weng Choy
|Kay Weng Choy
|
|
|Complete (
|
|Complete
|
|
|
|
|
|
Line 2,217: Line 2,299:
|Kay Weng Choy
|Kay Weng Choy
|
|
|Complete (
|
|Complete
|
|
|
|
|
|
Line 2,224: Line 2,309:
|Gordana
|Gordana
|
|
|Complete (
|
|Complete
|
|
|
|
|
|
Line 2,231: Line 2,319:
|Paul De Fazio
|Paul De Fazio
|
|
|Complete (
|
|Complete
|
|
|
|
|
|
Line 2,238: Line 2,329:
|Paul De Fazio
|Paul De Fazio
|
|
|Complete (
|
|Complete
|
|
|
|
|
|
Line 2,245: Line 2,339:
|Brian Davis
|Brian Davis
|
|
|Complete (12/5/18)
|
|Complete
|12/5/18
|
|
|
|
|
Line 2,252: Line 2,349:
|Brian Davis
|Brian Davis
|
|
|Complete (8/3/18)
|
|Complete
|8/3/18
|
|
|
|
|
Line 2,259: Line 2,359:
|Brian Davis
|Brian Davis
|
|
|Complete (6/9/19)
|
|Complete
|6/9/19
|
|
|
|
|
Line 2,266: Line 2,369:
|Brian Davis
|Brian Davis
|
|
|Complete (10/1/18)
|
|Complete
|10/1/18
|
|
|
|
|
Line 2,273: Line 2,379:
|Brian Davis
|Brian Davis
|
|
|Complete (8/2/18)
|
|Complete
|8/2/18
|
|
|
|
|
Line 2,280: Line 2,389:
|Kay Weng Choy
|Kay Weng Choy
|
|
|Complete (
|
|Complete
|
|
|
|
|
|
Line 2,286: Line 2,398:
|PTEN
|PTEN
|Beth Pitel
|Beth Pitel
|
|
|
|Pending
|Pending
|
|
|
|
|
|
|-
|-
|MLTT3
|MLTT3
|
|
|
|
|
|
|
Line 2,300: Line 2,418:
|MECOM
|MECOM
|Brian Davis
|Brian Davis
|
|
|
|Pending
|Pending
|
|
|
|
|
|
Line 2,307: Line 2,428:
|FGFR1(FLT2)
|FGFR1(FLT2)
|Brian Davis
|Brian Davis
|
|
|
|Pending
|Pending
|
|
|
|
|
|
|-
|-
|KMT2A
|KMT2A
|
|
|
|
|
|
|
Line 2,320: Line 2,447:
|-
|-
|DEK
|DEK
|Wahab A. Khan
|
|
|
|Pending
|
|
|
|
Line 2,327: Line 2,457:
|-
|-
|NUP214
|NUP214
|Wahab A. Khan
|
|
|
|Pending
|
|
|
|
Line 2,334: Line 2,467:
|-
|-
|RBM15
|RBM15
|
|
|
|
|
|
|
Line 2,341: Line 2,477:
|-
|-
|MKL1
|MKL1
|
|
|
|
|
|
|
Line 2,348: Line 2,487:
|-
|-
|DDX41
|DDX41
|Ying Zou
|8/7/20
|
|
|Pending
|
|
|
|
Line 2,355: Line 2,497:
|-
|-
|ANKRD26
|ANKRD26
|
|
|
|
|
|
|
Line 2,362: Line 2,507:
|-
|-
|CUX1
|CUX1
|
|
|
|
|
|
|
Line 2,369: Line 2,517:
|-
|-
|TET2
|TET2
|
|
|
|
|
|
|
Line 2,376: Line 2,527:
|-
|-
|EZH2
|EZH2
|
|
|
|
|
|
|
Line 2,383: Line 2,537:
|-
|-
|FOXP1
|FOXP1
|
|
|
|
|
|
|
Line 2,390: Line 2,547:
|-
|-
|MYC
|MYC
|
|
|
|
|
|
|
Line 2,397: Line 2,557:
|-
|-
|JAK2
|JAK2
|
|
|
|
|
|
|
Line 2,404: Line 2,567:
|-
|-
|WT1
|WT1
|DONE
|
|
|
|DONE
|
|
|
|
Line 2,411: Line 2,577:
|-
|-
|CBL
|CBL
|
|
|
|
|
|
|
Line 2,418: Line 2,587:
|-
|-
|NF1
|NF1
|
|
|
|
|
|
|
Line 2,425: Line 2,597:
|-
|-
|SUZ12
|SUZ12
|
|
|
|
|
|
|
Line 2,432: Line 2,607:
|-
|-
|ERG
|ERG
|
|
|
|
|
|
|
Line 2,439: Line 2,617:
|-
|-
|EST2
|EST2
|
|
|
|
|
|
|
Line 2,446: Line 2,627:
|-
|-
|RPS14
|RPS14
|
|
|
|
|
|
|
Line 2,453: Line 2,637:
|-
|-
|RB1
|RB1
|
|
|
|
|
|
|
Line 2,460: Line 2,647:
|-
|-
|MPL
|MPL
|
|
|
|
|
|
|
Line 2,467: Line 2,657:
|-
|-
|CHGA
|CHGA
|
|
|
|
|
|
|
Line 2,474: Line 2,667:
|-
|-
|CDH1
|CDH1
|
|
|
|
|
|
|
Line 2,481: Line 2,677:
|-
|-
|SRSF2
|SRSF2
|
|
|
|
|
|
|
Line 2,488: Line 2,687:
|-
|-
|DNMT1
|DNMT1
|
|
|
|
|
|
|
Line 2,495: Line 2,697:
|-
|-
|PRDX2
|PRDX2
|
|
|
|
|
|
|
Line 2,502: Line 2,707:
|-
|-
|ASXL1
|ASXL1
|DONE
|
|
|
|DONE
|
|
|
|
Line 2,509: Line 2,717:
|-
|-
|MN1
|MN1
|
|
|
|
|
|
|
Line 2,516: Line 2,727:
|-
|-
|SF3A1
|SF3A1
|
|
|
|
|
|
|
Line 2,523: Line 2,737:
|-
|-
|EP300
|EP300
|
|
|
|
|
|
|
Line 2,530: Line 2,747:
|-
|-
|JARID2
|JARID2
|
|
|
|
|
|
|
Line 2,536: Line 2,756:
|
|
|-
|-
|BRCA1
|
|
|
|
|
|
Line 2,543: Line 2,766:
|
|
|-
|-
|BRCA2
|
|
|
|
|
|
Line 2,550: Line 2,776:
|
|
|-
|-
|
|
|
|
|
|
|
Line 2,557: Line 2,786:
|
|
|-
|-
|
|
|
|
|
|
|
Retrieved from "https://test.ccga.io/index.php/Volunteer_Assignments_and_Opportunities"